Viral pneumonia
Drug research and approvals for viral pneumonia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 279 studies of viral pneumonia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 279
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Improving Vaccine Efficacy for People With Helminth Infection: CORBEVAX in EthiopiaNCT07948395 · Phase 2 / Phase 3 · University of Aarhus · starts Oct 10, 2026
- Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious…NCT07932002 · Phase 4 · IMMUNOe Research Centers · starts Nov 5, 2025
- CEDRN Pandemic Preparedness RegistryNCT07933861 · Not reported · University of British Columbia · starts Sep 1, 2026
- Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility StudyNCT07874217 · Not applicable · Oxford Brookes University · starts Oct 5, 2026
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsNCT07863635 · Phase 4 · ModernaTX, Inc. · starts Oct 9, 2026
- Clinical and Therapeutic Outcomes by Molecular Subtype in Breast CancerNCT07856225 · Not reported · Fundación Santa Fe de Bogota · starts Dec 1, 2025
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years…NCT07808697 · Phase 2 · ModernaTX, Inc. · starts Sep 4, 2026
- Long-Term Study of COVID-19 Infection and Long COVIDNCT07781501 · Not reported · University of North Carolina, Chapel Hill · starts Nov 20, 2026
- Fatigue Investigation Using Digital OutcomesNCT07783074 · Not reported · Liliana Barrios · starts May 26, 2026
Phase 3 5
- HydroxychloroquineFerriprotoporphyrin IX inhibitor
- AzithromycinBacterial 70S ribosome inhibitor
- RavulizumabComplement C5 inhibitor
- DexamethasoneGlucocorticoid receptor agonist
- ReparixinInterleukin-8 receptor A modulator
Phase 2 12 of 13
- Nitric oxideSoluble guanylate cyclase activator
- MefloquineFerriprotoporphyrin IX inhibitor
- ClopidogrelPurinergic receptor P2Y12 antagonist
- FondaparinuxAntithrombin-III activator
- TocilizumabInterleukin-6 receptor alpha subunit inhibitor
- PrednisoneGlucocorticoid receptor agonist
- ChloroquineFerriprotoporphyrin IX inhibitor
- TirofibanIntegrin alpha-IIb/beta-3 inhibitor
- ColchicineTubulin inhibitor
- AspirinCyclooxygenase inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
Phase 1 or earlier 3
- RemdesivirRNA-directed RNA polymerase L inhibitor
- FavipiravirRNA-directed RNA polymerase inhibitor
- Taniraleucel
How its trials ended
136 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 37 whose ending is known, 16% met their primary endpoint, 14% missed it and 70% stopped early.
- Completed, result not reported5037%
- Status unknown3929%
- Stopped: other or unclear1612%
- Ongoing107%
- Met its primary endpoint64%
- Missed its primary endpoint54%
- Stopped: lack of efficacy54%
- Stopped: enrollment or feasibility32%
- Stopped: sponsor or business decision21%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA